Oxprenolol hydrochloride

Base Information

• Chemical Name: Oxprenolol hydrochloride
• CAS No.: 6452-73-9
• Molecular Formula: C15H24ClNO3
• Molecular Weight: 301.813
• Hs Code.: 2922190900
• European Community (EC) Number: 229-260-5,245-358-0
• UNII: F4XSI7SNIU
• DSSTox Substance ID: DTXSID5021093
• Wikidata: Q27277643
• NCI Thesaurus Code: C66277
• ChEMBL ID: CHEMBL1200745
• Mol file: 6452-73-9.mol

Synonyms:Coretal;Hydrochloride, Oxprenolol;Koretal;Oxprenolol;Oxprenolol Hydrochloride;Slow Trasicor;Tevacor;Trasicor;Trasicor, Slow

Chemical Property of Oxprenolol hydrochloride

Chemical Property:

• Appearance/Colour: White Solid
• Melting Point: 91-93 °C
• Boiling Point: 403.3 °C at 760 mmHg
• Flash Point: 197.7 °C
• PSA: 50.72000
• LogP: 3.18200
• Storage Temp.: Store at +4°C
• Solubility.: Very soluble in water, freely soluble in alcohol.
• Hydrogen Bond Donor Count: 3
• Hydrogen Bond Acceptor Count: 4
• Rotatable Bond Count: 9
• Exact Mass: 301.1444713
• Heavy Atom Count: 20
• Complexity: 246

Purity/Quality:

99%, ^*data from raw suppliers

Oxprenolol hydrochloride ^*data from reagent suppliers

Safty Information:

• Pictogram(s): Xi
• Hazard Codes: Xi

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CC(C)NCC(COC1=CC=CC=C1OCC=C)O.Cl
• Description: Oxprenolol is an orally bioavailable β-adrenergic receptor (β-AR) antagonist (Ki = 7.10 nM in a radioligand binding assay using rat heart tissue). It is non-selective and binds to both β1- and β2-ARs (Kds = 2.09 and 1.35 nM in isolated rat heart and uterus, respectively). Oxprenolol is selective for β-ARs over serotonin (5-HT) receptors in rat sarcolemmal membrane preparations (IC50s = 4.13 and 23,300 nM, respectively), but it binds to 5-HT1A receptors in rat hippocampus and 5-HT1B in rat striatum (Kis = 94.2 and 642 nM, respectively). Formulations containing oxprenolol have been used to treat hypertension and angina pectoris.
• Uses: Antihypertensive;Adrenergic receptor antagonist
• Therapeutic Function: Antiarrhythmic
• Clinical Use: Beta-1 adrenoceptor blocker: Hypertension Angina Arrhythmias Anxiety
• Drug interactions: Potentially hazardous interactions with other drugs Anaesthetics: enhanced hypotensive effect. Analgesics: NSAIDs antagonise hypotensive effect. Anti-arrhythmics: increased risk of myocardial depression and bradycardia; increased risk of bradycardia, myocardial depression and AV block with amiodarone; increased risk of myocardial depression and bradycardia with flecainide. Antidepressants: enhanced hypotensive effect with MAOIs. Antihypertensives: enhanced hypotensive effect; increased risk of first dose hypotensive effect with post-synaptic alpha-blockers such as prazosin; increased risk of withdrawal hypertension with clonidine; increased risk of bradycardia and AV block with diltiazem; severe hypotension and heart failure occasionally with nifedipine; asystole, severe hypotension and heart failure with verapamil. Antimalarials: increased risk of bradycardia with mefloquine. Antipsychotics: enhanced hypotensive effect with phenothiazines. Cytotoxics: possible increased risk of bradycardia with crizotinib. Diuretics: enhanced hypotensive effect. Fingolimod: possibly increased risk of bradycardia. Moxisylyte: possibly severe postural hypotension. Sympathomimetics: severe hypertension with adrenaline and noradrenaline (especially with nonselective beta-blockers) and possibly with dopamine.